{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:16:03Z","timestamp":1771038963688,"version":"3.50.1"},"reference-count":88,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Neurol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immune-mediated neuropathies encompass a range of neurological disorders, including chronic inflammatory demyelinating polyradiculoneuropathy, Guillain\u2013Barr\u00e9 syndrome, multifocal motor neuropathy, autoimmune autonomic neuropathies, and paranodal nodopathies. Recognizing clinical patterns is key to narrowing the broad range of differential diagnoses in immune-mediated neuropathies. Electrodiagnostic testing is a useful tool to support the diagnosis of immune-mediated neuropathies. Our understanding of autoimmune demyelinating neuropathies is rapidly advancing, particularly with the discovery of nodal and paranodal antibodies. Recent advances in neuropathy treatment include the utilization of neonatal Fc receptors to reduce antibody recycling, and the development of complement inhibitors to reduce inflammatory damage, offering promising new therapeutic avenues. Timely identification of immune-mediated neuropathies is imperative as delay in diagnosis and treatment may lead to irreversible disability.<\/jats:p>","DOI":"10.1055\/s-0044-1791579","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T22:52:08Z","timestamp":1729205528000},"page":"122-131","source":"Crossref","is-referenced-by-count":1,"title":["Immune-Mediated Neuropathies: Top 10 Clinical Pearls"],"prefix":"10.1055","volume":"45","author":[{"given":"Elizabeth M.","family":"Monohan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Columbia University Irving Medical Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Thomas H.","family":"Brannagan","sequence":"additional","affiliation":[{"name":"Vagelos College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1111\/ene.16073","article-title":"European Academy of Neurology\/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barr\u00e9 syndrome","volume":"30","author":"P A van Doorn","year":"2023","journal-title":"Eur J Neurol"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"J J Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/brain\/awy232","article-title":"Regional variation of Guillain-Barr\u00e9 syndrome","volume":"141","author":"A Y Doets","year":"2018","journal-title":"Brain"},{"issue":"9497","key":"ref4","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"R AC Hughes","year":"2005","journal-title":"Lancet"},{"issue":"06","key":"ref5","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/mus.20762","article-title":"Ganglioside mimicry and peripheral nerve disease","volume":"35","author":"N Yuki","year":"2007","journal-title":"Muscle Nerve"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s100720070081","article-title":"Guillain-Barr\u00e9 syndrome: an Italian multicentre case-control study","volume":"21","author":"Guillain-Barre Syndrome Study Group","year":"2000","journal-title":"Neurol Sci"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"e1299","DOI":"10.1212\/WNL.0000000000200885","article-title":"An international perspective on preceding infections in Guillain-Barr\u00e9 syndrome: the IGOS-1000 cohort","volume":"99","author":"S E Leonhard","year":"2022","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s41983-023-00764-x","article-title":"Seroprevalence of Campylobacter jejuni infection in common subtypes of Guillain\u2013Barre syndrome in Kashmiri population","volume":"59","author":"F Mir","year":"2023","journal-title":"Egypt J Neurol Psychiatr Neurosurg"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.3390\/microorganisms10112139","article-title":"Campylobacter jejuni infection, anti-ganglioside antibodies, and neuropathy","volume":"10","author":"N Latov","year":"2022","journal-title":"Microorganisms"},{"issue":"11","key":"ref10","doi-asserted-by":"crossref","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","article-title":"Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies","volume":"93","author":"D Dubey","year":"2019","journal-title":"Neurology"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00415-020-09911-3","article-title":"Guillain-Barr\u00e9 syndrome in the COVID-19 era: just an occasional cluster?","volume":"268","author":"G L Gigli","year":"2021","journal-title":"J Neurol"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/jnnp-2020-324837","article-title":"Guillain-Barr\u00e9 syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions","volume":"92","author":"M Filosto","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1125455","DOI":"10.3389\/fneur.2023.1125455","article-title":"Incidence of Guillain-Barr\u00e9 syndrome in South Korea during the early COVID-19 pandemic","volume":"14","author":"S A Choi","year":"2023","journal-title":"Front Neurol"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000527726","article-title":"Decreased incidence of Guillain-Barr\u00e9 syndrome during the COVID-19 pandemic: a retrospective population-based study","volume":"57","author":"B Hafsteinsd\u00f3ttir","year":"2023","journal-title":"Neuroepidemiology"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/brain\/awaa433","article-title":"Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barr\u00e9 syndrome","volume":"144","author":"S Keddie","year":"2021","journal-title":"Brain"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps","volume":"15","author":"S E Leonhard","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12028-019-00781-w","article-title":"Dysautonomia in Guillain-Barr\u00e9 syndrome: prevalence, clinical spectrum, and outcomes","volume":"32","author":"T Chakraborty","year":"2020","journal-title":"Neurocrit Care"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1136\/jnnp-2022-329937","article-title":"Modified Erasmus GBS Respiratory Insufficiency Score: a simplified clinical tool to predict the risk of mechanical ventilation in Guillain-Barr\u00e9 syndrome","volume":"94","author":"L WG Luijten","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1474-4422(20)30494-4","article-title":"Second intravenous immunoglobulin dose in patients with Guillain-Barr\u00e9 syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial","volume":"20","author":"C Walgaard","year":"2021","journal-title":"Lancet Neurol"},{"issue":"05","key":"ref20","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1212\/WNL.0000000000013139","article-title":"Predicting outcome in Guillain-Barr\u00e9 syndrome: international validation of the Modified Erasmus GBS Outcome Score","volume":"98","author":"A Y Doets","year":"2022","journal-title":"Neurology"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/CND.0000000000000451","article-title":"Neonatal Fc receptor inhibitor therapeutics in neuromuscular disease","volume":"24","author":"M Jaffry","year":"2023","journal-title":"J Clin Neuromuscul Dis"},{"issue":"06","key":"ref22","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1007\/s00415-024-12321-4","article-title":"Efgartigimod in the treatment of Guillain-Barr\u00e9 syndrome","volume":"271","author":"H Zhang","year":"2024","journal-title":"J Neurol"},{"key":"ref23","volume-title":"Evaluating Efgartigimod in Patients With Guillain-Barr\u00e9 Syndrome","author":"C Karam"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/cen3.12587","article-title":"Guillain-Barr\u00e9 syndrome: novel treatment by complement inhibition","volume":"11","author":"S Misawa","year":"2020","journal-title":"Clin Exp Neuroimmunol"},{"issue":"06","key":"ref25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1474-4422(18)30114-5","article-title":"Safety and efficacy of eculizumab in Guillain-Barr\u00e9 syndrome: a multicentre, double-blind, randomised phase 2 trial","volume":"17","author":"S Misawa","year":"2018","journal-title":"Lancet Neurol"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1212\/WNL.0b013e3181aaea47","article-title":"Incidence and prevalence of CIDP and the association of diabetes mellitus","volume":"73","author":"R S Laughlin","year":"2009","journal-title":"Neurology"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1529-8027.2010.00251.x","article-title":"A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"15","author":"K Viala","year":"2010","journal-title":"J Peripher Nerv Syst"},{"issue":"06","key":"ref28","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1111\/ene.14796","article-title":"Misdiagnosis and diagnostic pitfalls of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"28","author":"M C Broers","year":"2021","journal-title":"Eur J Neurol"},{"issue":"06","key":"ref29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/mus.27374","article-title":"Antecedent infections and vaccinations in chronic inflammatory demyelinating polyneuropathy: a European collaborative study","volume":"64","author":"Y A Rajabally","year":"2021","journal-title":"Muscle Nerve"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/mus.24068","article-title":"Pathophysiology of immune-mediated demyelinating neuropathies\u2013Part II: Neurology","volume":"49","author":"H Franssen","year":"2014","journal-title":"Muscle Nerve"},{"issue":"11","key":"ref31","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1111\/ene.14959","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision","volume":"28","author":"P YK Van den Bergh","year":"2021","journal-title":"Eur J Neurol"},{"key":"ref32","first-page":"619","volume-title":"Acute\/chronic inflammatory polyradiculoneuropathy","author":"C Miranda","year":"2023"},{"key":"ref33","first-page":"26","article-title":"Optimizing the use of outcome measures in chronic inflammatory demyelinating polyneuropathy","volume":"13","author":"J Allen","year":"2017","journal-title":"US Neurology"},{"issue":"02","key":"ref34","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/mus.24207","article-title":"INCAT disability score: a critical analysis of its measurement properties","volume":"50","author":"A Breiner","year":"2014","journal-title":"Muscle Nerve"},{"issue":"04","key":"ref35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","article-title":"Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies","volume":"76","author":"S I van Nes","year":"2011","journal-title":"Neurology"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jns.12608","article-title":"Prognostic value of neurofilament light in blood in patients with polyneuropathy: a systematic review","volume":"29","author":"L S Kodal","year":"2024","journal-title":"J Peripher Nerv Syst"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"e16023","DOI":"10.1111\/ene.16023","article-title":"Serum neurofilament light chain does not detect self-reported treatment-related fluctuations in chronic inflammatory demyelinating polyneuropathy","volume":"31","author":"P L Poser","year":"2024","journal-title":"Eur J Neurol"},{"issue":"03","key":"ref38","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.1212\/WNL.0000000000011090","article-title":"Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis","volume":"96","author":"S Ticau","year":"2021","journal-title":"Neurology"},{"issue":"06","key":"ref39","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1474-4422(12)70093-5","article-title":"Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial","volume":"11","author":"E Nobile-Orazio","year":"2012","journal-title":"Lancet Neurol"},{"issue":"05","key":"ref40","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/mus.21277","article-title":"Current treatments of chronic immune-mediated demyelinating polyneuropathies","volume":"39","author":"T H Brannagan III","year":"2009","journal-title":"Muscle Nerve"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/brain\/awab422","article-title":"Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy","volume":"145","author":"D R Cornblath","year":"2022","journal-title":"Brain"},{"issue":"03","key":"ref42","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/jns.12573","article-title":"Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: the ADVANCE-CIDP 1 randomized controlled trial","volume":"28","author":"V Bril","year":"2023","journal-title":"J Peripher Nerv Syst"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","article-title":"Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"I N van Schaik","year":"2018","journal-title":"Lancet Neurol"},{"issue":"06","key":"ref44","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1212\/WNL.0000000000001833","article-title":"CIDP diagnostic pitfalls and perception of treatment benefit","volume":"85","author":"J A Allen","year":"2015","journal-title":"Neurology"},{"issue":"04","key":"ref45","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/mus.25271","article-title":"Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy","volume":"55","author":"A Kaplan","year":"2017","journal-title":"Muscle Nerve"},{"issue":"02","key":"ref46","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1212\/WNL.48.2.321","article-title":"Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy","volume":"48","author":"K C Gorson","year":"1997","journal-title":"Neurology"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"J A Allen","year":"2024","journal-title":"Lancet Neurol"},{"issue":"06","key":"ref48","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1212\/WNL.51.6.1735","article-title":"Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy","volume":"51","author":"J L Good","year":"1998","journal-title":"Neurology"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1212\/WNL.0000000000204596","article-title":"Preliminary efficacy and safety data from the phase 2 trial of riliprubart (SAR445088), a humanized monoclonal antibody targeting complement C1s, in chronic inflammatory demyelinating polyneuropathy (CIDP) (S15.008)","volume":"102","author":"L Querol","year":"2024","journal-title":"Neurology"},{"issue":"05","key":"ref50","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/WCO.0000000000000975","article-title":"Antibody testing in neuropathy associated with anti-myelin-associated glycoprotein antibodies: where we are after 40 years","volume":"34","author":"N Latov","year":"2021","journal-title":"Curr Opin Neurol"},{"key":"ref51","first-page":"295","volume-title":"Antibodies to glycoconjugates in neuropathy and motor neuron disease","author":"N Latov","year":"1994"},{"issue":"09","key":"ref52","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s00415-016-8187-z","article-title":"Is distal motor and\/or sensory demyelination a distinctive feature of anti-MAG neuropathy?","volume":"263","author":"P Lozeron","year":"2016","journal-title":"J Neurol"},{"issue":"03","key":"ref53","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/1097-4598(200103)24:3<311::AID-MUS1001>3.0.CO;2-A","article-title":"Clinical spectrum of chronic acquired demyelinating polyneuropathies","volume":"24","author":"D S Saperstein","year":"2001","journal-title":"Muscle Nerve"},{"issue":"06","key":"ref54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0043-1777728","article-title":"Anti-MAG neuropathy: historical aspects, clinical-pathological correlations, and considerations for future therapeutical trials","volume":"82","author":"N Latov","year":"2024","journal-title":"Arq Neuropsiquiatr"},{"issue":"01","key":"ref55","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3324\/haematol.2019.243139","article-title":"Chemoimmunotherapy with rituximab, cyclophosphamide and prednisolone in IgM paraproteinaemic neuropathy: evidence of sustained improvement in electrophysiological, serological and functional outcomes","volume":"106","author":"N TH Colchester","year":"2021","journal-title":"Haematologica"},{"issue":"10","key":"ref56","first-page":"CD002827","article-title":"Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies","volume":"10","author":"M P Lunn","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"ref57","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1007\/s00415-020-10041-z","article-title":"Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera","volume":"267","author":"E Delmont","year":"2020","journal-title":"J Neurol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/brain\/awv054","article-title":"Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia","volume":"138","author":"Y Miura","year":"2015","journal-title":"Brain"},{"issue":"S 03","key":"ref59","first-page":"S23","article-title":"Autoimmune nodo-paranodopathies 10\u2009years later: clinical features, pathophysiology and treatment","volume":"28","author":"A Uncini","year":"2023","journal-title":"J Peripher Nerv Syst"},{"issue":"01","key":"ref60","doi-asserted-by":"crossref","first-page":"e639","DOI":"10.1212\/NXI.0000000000000639","article-title":"Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: clinical relevance of IgG isotype","volume":"7","author":"A Cortese","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"09","key":"ref61","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1212\/WNL.0000000000002418","article-title":"Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy","volume":"86","author":"J J Devaux","year":"2016","journal-title":"Neurology"},{"issue":"09","key":"ref62","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1212\/WNL.0b013e3181f0738e","article-title":"Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy","volume":"75","author":"E A Cats","year":"2010","journal-title":"Neurology"},{"issue":"02","key":"ref63","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/jnnp-2019-321532","article-title":"Multifocal motor neuropathy: controversies and priorities","volume":"91","author":"W Z Yeh","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"07","key":"ref64","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/jnnp-2013-305755","article-title":"Sensitivity and predictive value of anti-GM1\/galactocerebroside IgM antibodies in multifocal motor neuropathy","volume":"85","author":"E Nobile-Orazio","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"04","key":"ref65","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1529-8027.2010.00290.x","article-title":"European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society \u2013 first revision","volume":"15","author":"Joint Task Force of the EFNS and the PNS","year":"2010","journal-title":"J Peripher Nerv Syst"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"117814","DOI":"10.1016\/j.jns.2021.117814","article-title":"Multifocal motor neuropathy: long-term treatment with subcutaneous immunoglobulin","volume":"429","author":"L Gentile","year":"2021","journal-title":"J Neurol Sci"},{"issue":"05","key":"ref67","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1212\/WNL.50.5.1480","article-title":"Deterioration of multifocal motor neuropathy after plasma exchange","volume":"50","author":"M Carpo","year":"1998","journal-title":"Neurology"},{"issue":"04","key":"ref68","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.3390\/ijms25042296","article-title":"Autoimmune autonomic neuropathy: from pathogenesis to diagnosis","volume":"25","author":"S Nakane","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"12","key":"ref69","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJM200009213431204","article-title":"Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies","volume":"343","author":"S Vernino","year":"2000","journal-title":"N Engl J Med"},{"issue":"20","key":"ref70","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1212\/01.wnl.0000312280.44805.5d","article-title":"Invited article: autonomic ganglia: target and novel therapeutic tool","volume":"70","author":"S Vernino","year":"2008","journal-title":"Neurology"},{"issue":"03","key":"ref71","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1152\/jn.00408.2003","article-title":"Experimental autoimmune autonomic neuropathy","volume":"90","author":"S Vernino","year":"2003","journal-title":"J Neurophysiol"},{"issue":"01","key":"ref72","first-page":"44","article-title":"Autoimmune autonomic disorders","volume":"26","author":"S Vernino","year":"2020","journal-title":"Continuum (Minneap Minn)"},{"issue":"01","key":"ref73","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/jnnp-2012-302833","article-title":"The spectrum of immune-mediated autonomic neuropathies: insights from the clinicopathological features","volume":"84","author":"H Koike","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"04","key":"ref74","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10286-009-0012-7","article-title":"Autoimmune autonomic ganglionopathy: treatment by plasma exchanges and rituximab","volume":"19","author":"R Imrich","year":"2009","journal-title":"Clin Auton Res"},{"issue":"23","key":"ref75","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1212\/WNL.0b013e3181a92b52","article-title":"Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy","volume":"72","author":"V Iodice","year":"2009","journal-title":"Neurology"},{"issue":"01","key":"ref76","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10286-017-0493-8","article-title":"Seronegative autoimmune autonomic neuropathy: a distinct clinical entity","volume":"28","author":"E P Golden","year":"2018","journal-title":"Clin Auton Res"},{"issue":"06","key":"ref77","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/mus.23502","article-title":"Paraneoplastic neuromuscular disorders","volume":"46","author":"L Sharp","year":"2012","journal-title":"Muscle Nerve"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"706169","DOI":"10.3389\/fneur.2021.706169","article-title":"Paraneoplastic neuropathies: What's New Since the 2004 recommended diagnostic criteria","volume":"12","author":"M Zoccarato","year":"2021","journal-title":"Front Neurol"},{"issue":"16","key":"ref79","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"A Marini","year":"2021","journal-title":"Neurology"},{"issue":"36","key":"ref80","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"B J Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref81","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1474-4422(23)00369-1","article-title":"Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes","volume":"23","author":"A Farina","year":"2024","journal-title":"Lancet Neurol"},{"issue":"03","key":"ref82","doi-asserted-by":"crossref","first-page":"e200423","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs","volume":"3","author":"A Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"1134436","DOI":"10.3389\/fimmu.2023.1134436","article-title":"Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years","volume":"14","author":"R Ruggiero","year":"2023","journal-title":"Front Immunol"},{"issue":"08","key":"ref84","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.clinph.2019.03.035","article-title":"Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy","volume":"130","author":"X Chen","year":"2019","journal-title":"Clin Neurophysiol"},{"issue":"07","key":"ref85","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1001\/jamaneurol.2015.0475","article-title":"Risk of neuropathy among 28,232 patients with biopsy-verified celiac disease","volume":"72","author":"S P Thawani","year":"2015","journal-title":"JAMA Neurol"},{"issue":"20","key":"ref86","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1212\/WNL.0000000000000970","article-title":"The neurologic significance of celiac disease biomarkers","volume":"83","author":"A McKeon","year":"2014","journal-title":"Neurology"},{"issue":"10","key":"ref87","first-page":"1574","article-title":"Small-fiber neuropathy\/neuronopathy associated with celiac disease: skin biopsy findings","volume":"62","author":"T H Brannagan III","year":"2005","journal-title":"Arch Neurol"},{"issue":"11","key":"ref88","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1212\/WNL.0b013e3181f25ee0","article-title":"Sensory ganglionopathy due to gluten sensitivity","volume":"75","author":"M Hadjivassiliou","year":"2010","journal-title":"Neurology"}],"container-title":["Seminars in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1791579.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T23:35:22Z","timestamp":1737156922000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1791579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":88,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2025,1,17]]},"published-print":{"date-parts":[[2025,2]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1791579","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0271-8235","1098-9021"],"issn-type":[{"value":"0271-8235","type":"print"},{"value":"1098-9021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,17]]}}}